Emerging Evidence on the Pathobiology of Mucositis

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2013 Jul 12

PMID 23842598

Citations 41

Authors

Noor Al-Dasooqi

Stephen T Sonis

Joanne M Bowen

Emma Bateman

Nicole Blijlevens

Rachel J Gibson

Richard M Logan

Raj G Nair

Andrea M Stringer

Roger Yazbeck

Sharon Elad

Rajesh V Lalla

Affiliations

Soon will be listed here.

Abstract

Background: Considerable progress has been made in our understanding of the biological basis for cancer therapy-induced mucosal barrier injury (mucositis). The last formal review of the subject by MASCC/ISOO was published in 2007; consequently, an update is timely.

Methods: Panel members reviewed the biomedical literature on mucositis pathobiology published between January 2005 and December 2011.

Results: Recent research has provided data on the contribution of tissue structure changes, inflammation and microbiome changes to the development of mucositis. Additional research has focused on targeted therapy-induced toxicity, toxicity clustering and the investigation of genetic polymorphisms in toxicity prediction. This review paper summarizes the recent evidence on these aspects of mucositis pathobiology.

Conclusion: The ultimate goal of mucositis researchers is to identify the most appropriate targets for therapeutic interventions and to be able to predict toxicity risk and personalize interventions to genetically suitable patients. Continuing research efforts are needed to further our understanding of mucositis pathobiology and the pharmacogenomics of toxicity.

Citing Articles

[Clinical analysis of oral mucositis after secondary allogeneic hematopoietic stem cell transplantation in patients with hematological diseases].

Zhu X, Wang J, Fu H, Han T, Xu Z, Zhang X Zhonghua Xue Ye Xue Za Zhi. 2025; 45(12):1078-1084.

PMID: 39765347 PMC: 11886692. DOI: 10.3760/cma.j.cn121090-20240701-00240.

Nutritional aspects in autoimmune diseases undergoing hematopoietic stem cell transplantation: overview and recommendations on behalf of the EBMT ADWP and Nurses Group.

Gandossi C, Jessop H, Hahn A, Heininger L, Henes J, Radaelli A Front Nutr. 2024; 11:1394518.

PMID: 38784130 PMC: 11111942. DOI: 10.3389/fnut.2024.1394518.

Preventive versus curative photobiomodulation for oral mucositis in patients with multiple myeloma undergoing hematopoietic stem cell transplantation: which approach is more effective?.

Rupel K, Cornacchia A, Poiani M, Mohamed S, De Bellis E, Ballerini M Support Care Cancer. 2024; 32(3):208.

PMID: 38438625 DOI: 10.1007/s00520-024-08414-5.

Secondary lesions of the mucous membrane of the oral cavity as a side effect of complex anticancer treatment: a literature review.

Helei N, Helei V, Zhulkevych I J Med Life. 2024; 16(11):1585-1590.

PMID: 38406781 PMC: 10893569. DOI: 10.25122/jml-2023-0060.

Dietary intake effects on severity of cancer treatment-induced mucositis: A cross-sectional study.

Manifar S, Tonkaboni A, Sobhanifar A, HafeziMotlagh K, Bitarafan S, Mazani M Health Sci Rep. 2023; 6(11):e1706.

PMID: 38028713 PMC: 10646840. DOI: 10.1002/hsr2.1706.

References

Gibson R, Keefe D, Thompson F, Clarke J, Goland G, Cummins A . Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci. 2002; 47(12):2751-7. DOI: 10.1023/a:1021061306913. View

Bowen J, Gibson R, Keefe D, Cummins A . Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology. 2005; 37(1):56-62. DOI: 10.1080/00313020400023461. View

Keefe D, Schubert M, Elting L, Sonis S, Epstein J, Raber-Durlacher J . Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007; 109(5):820-31. DOI: 10.1002/cncr.22484. View

Fiocchi C . Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998; 115(1):182-205. DOI: 10.1016/s0016-5085(98)70381-6. View

Al-Dasooqi N, Bowen J, Gibson R, Logan R, Stringer A, Keefe D . Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the Dark Agouti rat. Int J Exp Pathol. 2011; 92(5):357-65. PMC: 3193150. DOI: 10.1111/j.1365-2613.2011.00771.x. View

van Vliet M, Harmsen H, de Bont E, Tissing W . The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog. 2010; 6(5):e1000879. PMC: 2877735. DOI: 10.1371/journal.ppat.1000879. View

Sonis S . The pathobiology of mucositis. Nat Rev Cancer. 2004; 4(4):277-84. DOI: 10.1038/nrc1318. View

Pico , Naccache . Mucositis: Its Occurrence, Consequences, and Treatment in the Oncology Setting. Oncologist. 1999; 3(6):446-451. View

Bochud P, Eggiman P, Calandra T, van Melle G, Saghafi L, Francioli P . Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis. 1994; 18(1):25-31. DOI: 10.1093/clinids/18.1.25. View

10.

Manzano M, Bueno P, Rueda R, Ramirez-Tortosa C, Prieto P, Lopez-Pedrosa J . Intestinal toxicity induced by 5-fluorouracil in pigs: a new preclinical model. Chemotherapy. 2007; 53(5):344-55. DOI: 10.1159/000107724. View

11.

West C, Dunning A, Rosenstein B . Genome-wide association studies and prediction of normal tissue toxicity. Semin Radiat Oncol. 2012; 22(2):91-9. DOI: 10.1016/j.semradonc.2011.12.007. View

12.

Ma T, Iwamoto G, Hoa N, Akotia V, Pedram A, Boivin M . TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. Am J Physiol Gastrointest Liver Physiol. 2004; 286(3):G367-76. DOI: 10.1152/ajpgi.00173.2003. View

13.

Anthony L, Bowen J, Garden A, Hewson I, Sonis S . New thoughts on the pathobiology of regimen-related mucosal injury. Support Care Cancer. 2006; 14(6):516-8. DOI: 10.1007/s00520-006-0058-1. View

14.

Schwab M, Zanger U, Marx C, Schaeffeler E, Klein K, Dippon J . Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol. 2008; 26(13):2131-8. DOI: 10.1200/JCO.2006.10.4182. View

15.

KERR J, Winterford C, Harmon B . Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994; 73(8):2013-26. DOI: 10.1002/1097-0142(19940415)73:8<2013::aid-cncr2820730802>3.0.co;2-j. View

16.

Murphy B . Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Support Oncol. 2007; 5(9 Suppl 4):13-21. View

17.

Soga Y, Maeda Y, Ishimaru F, Tanimoto M, Maeda H, Nishimura F . Bacterial substitution of coagulase-negative staphylococci for streptococci on the oral mucosa after hematopoietic cell transplantation. Support Care Cancer. 2010; 19(7):995-1000. DOI: 10.1007/s00520-010-0923-9. View

18.

Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D . Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science. 2001; 293(5528):293-7. DOI: 10.1126/science.1060191. View

19.

Zhao J, Huang L, Belmar N, Buelow R, Fong T . Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Clin Cancer Res. 2004; 10(8):2851-9. DOI: 10.1158/1078-0432.ccr-03-0496. View

20.

Toi M, Iwata H, Fujiwara Y, Ito Y, Nakamura S, Tokuda Y . Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer. 2009; 101(10):1676-82. PMC: 2778543. DOI: 10.1038/sj.bjc.6605343. View